$28.13−0.30 (−1.07%)
Market open · 15-min delayed · as of 3:53 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.
Parabilis Medicines (PBLS) Stock
Industry: Pharmaceutical Preparations
Sources Company filings, market prices and computed by Tenet Filings, prices and TenetHow we compute thisNot investment advice
Parabilis Medicines Inc. isn't scored yet Not enough ingested fundamentals to compute a Tenet Score for this stock.
Tenet Score
Not scored. We do not hold normalized financials for this listing, so the Tenet value screens do not apply. That is usually a foreign-domiciled ADR or a very new listing. Its price, chart, and news below are its own.
Price
Loading chart…
P/E
—
no P/E on file
P/B
—
no P/B on file
P/S
—
no P/S on file
ROE
—
no ROE for this year, and Tenet does not compute one yet
Operating margin
—
no operating margin on file
Net margin
—
no net margin on file
Current ratio
—
no current ratio on file
Net debt / EBITDA
—
no leverage ratio on file
EPS CAGR 5y
—
needs five years of positive earnings
Market cap
—
no market cap on file
Div yield
—
no yield on file
52-wk range
—
no 52-week range on file
The rest of this report
Which sections of this report have data for this listing, and a live peek at each.
About Parabilis Medicines Inc.
We are a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a nov…
Not investment advice.




